


The answer to cancer is research



Dear Friends,



David Abramson
President, ICRF
International

It will shock no one to state that the last 18 months have been some of the most challenging times many of us have ever encountered in our lifetimes. Together, we have seen the horrific effects of the pandemic on our families, friends, colleagues, businesses, and communities. We also know all too well that the pandemic is still not behind us.

But this is not a message of despair. Just the opposite. The message of ICRF and our brilliant scientists and researchers is filled with some of the greatest promises of hope, discovery, and success we have yet to see in our ongoing battle against cancer. It is a story of heroic effort, determination, and dedication... often bearing some of the most amazing accomplishments ever seen in cancer research.

Israel remains at the forefront in the fight against COVID-19. The entire world watches Israel daily as the shining example of vaccine rollouts, ongoing collection and analysis of scientific data, and longer-range planning. Many of our scientists in Israel have been involved in this effort, sharing their brilliance, knowledge, and lab facilities. Their contributions to the fight against COVID-19 are incomparable. This did not come without a cost, however. The numerous and lengthy quarantines caused precious delays in their ongoing cancer research. These setbacks sadly add to the tragedy of lost lives from the deadliest pandemic of them all, cancer.

Despite the many challenges arising from the pandemic, and the threat of new variants, our cancer researchers still triumphed. For example, Professor Efrat Shema is continuing her important research on pediatric gliomas, which you can read about on page 5. Likewise, Professor David Meiri is investigating a distinct combination of cannabinoids, which are able to induce cell death in leukemia cells. You can read more about this on page 6. In the darkness of the pandemic, our cancer scientists remain the guiding light for the rest of the world.

Israeli cancer scientists and researchers are clearly doing their job. And the staff and lay leaders of ICRF are doing their job. We therefore call upon you, our generous partners and donors, to excel at your job...

Please continue to support ICRF's efforts. If ever there was a time that proved the remarkable success of our sponsored scientists in challenging circumstances, it is now. We have a responsibility at ICRF to help our cancer scientists in Israel make up for lost time and efforts so they can continue on the road to success and key cancer breakthroughs. And they can only do this with your meaningful and generous financial support.

Together in partnership,

The message of ICRF and our brilliant scientists and researchers is filled with some of the greatest promises of hope, discovery, and success we have yet to see in our ongoing battle against cancer.

If ever there was a time that proved the remarkable success of our sponsored scientists in challenging circumstances, it is now.



Bryna Goldberg
Chair, ICRF
International



Beryl P. Chernov
ICRF National
Executive Director

David Abramson
President,
ICRF International


Bryna Goldberg
Chair,
ICRF International

Beryl P. Chernov
ICRF National
Executive Director

Making an Impact

Over
2,600
grants
funded
to date

Over
\$82 million
in funding awarded to date for
groundbreaking cancer research conducted
at every leading institution across Israel.



75
cancer
research
projects
funded
2021-
2022



- 2 Acceleration Grants
- 9 Research Professorship Grants
- 13 Research Career Development Awards (RCDAs)
- 30 Project Grants
- 6 Postdoctoral Fellowships
- 8 Collaborative Research Partnership Grants
- 6 Named Grants
- 1 Clinical Research Career Development Award (CRCDA)

Among the areas of cancer research being supported are studies in blood, brain, breast, colorectal, lung, ovarian, pancreatic, and skin cancers, as well as genetics and genomics, molecular biology, immunology and immunotherapy, and the tumor microenvironment.

Collaborative Research Partnership Grants

CONQUER
CANCER®
THE ASCO FOUNDATION

ICRF-Conquer Cancer (The ASCO Foundation) Career Development Award Grant
\$200,000 over a 3-year period to support an Israeli early-career faculty investigator to establish an independent clinical cancer research program.



Max Ritvo, Alan Slifka & Desiree Dato Fund for Fusion-Oncoprotein Cancers and Metastasis Grants – A Partnership Between ICRF, The Samuel Waxman Cancer Research Foundation, and The Alan B. Slifka Foundation
\$250,000 over a 2-year period to support collaborative science conducted by co-investigators based in the U.S. and Israel, with a focus on cancers driven by fusion oncoproteins in Ewing's sarcoma or metastatic cancer.

The ALAN B. SLIFKA
FOUNDATION



ICRF-City of Hope Jacki & Bruce Barron Cancer Research Scholars' Program Grants
\$440,000 over a 2-year period to support collaborative science conducted by co-investigators, one at City of Hope in the U.S. and the other in Israel, in order to advance our understanding of cancer and develop life-saving therapies, novel diagnostic approaches or prevention strategies.



ICRF-Cancer Research Institute Immunotherapy Promise Grants
\$150,000 over a 2-year period to support outstanding basic, pre-clinical, or translational research in cancer immunology and immunotherapy conducted by established, mid-level or senior Israeli scientists.

The Immunotherapy Promise™



ICRF-Israel Ministry of Science and Technology Geshar Grant for Academic Excellence in the Field of Cancer Research
NIS 600,000 over a 3-year period to support outstanding Israeli cancer scientists living abroad who wish to return to Israel to develop an independent research program.

Named Grants

Brause Family Initiative for Quality of Life Grants

\$275,000 over a 3-year period to support established Israeli investigators studying cancer treatment related to pain, side effects, and emotional problems experienced by cancer patients in order to maintain the best possible quality of life, with an emphasis on non-opioid solutions.

Len & Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers Grants

\$315,000 over a 3-year period to support established Israeli investigators studying the biology, diagnosis, treatment, or prevention of ovarian and/or uterine/MMMT cancers.

Barbara S. Goodman Endowed Research Career Development Award for Pancreatic Cancer

\$148,000 over a 3-year period to support a young Israeli scientist embarking on an independent research career with a particular focus on the biology, diagnosis, treatment, supportive care, and/or prevention of pancreatic cancer.

Beverly Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers

\$315,000 over a 3-year period to support established Israeli investigators studying the diagnosis and/or treatment of ovarian and female reproductive system cancers.

Selecting the Best Science



Nancy Maizels, PhD
Chair, ICRF International Scientific Council; Chair, ICRF Scientific Review Panel C; Professor of Immunology and Biochemistry Emerita, University of Washington School of Medicine, Seattle

The mission of ICRF is to fund the very best cancer research conducted by scientists at leading institutions throughout Israel. The scientific peer review process is central to this mission. It's my honor to serve as the Chair of the ICRF International Scientific Council (ISC), a group of scientists and physician-scientists who provide scientific leadership to ICRF and oversee the peer review process to ensure that it is both transparent and fair.

The first step in peer review is detailed evaluation of each proposal by one of the three Scientific Review Panels (SRPs). SRP members are leading U.S. and Canadian scientists from all fields of cancer research, who generously agree to commit their time to provide rigorous and detailed written reviews of 6 to 8 proposals each year. SRPs meet in March to critically discuss proposals and assign priority scores based on the significance and potential impact of the research for cancer, the qualifications of the applicant, the available infrastructure and intellectual environment, and the budget. Scores from all panels are merged into a priority list that identifies top candidates for funding. The next step is that the ISC evaluates the priority list and makes formal recommendations to the ICRF International Board of Trustees. Finally, the Board allocates funds. This multi-step process — SRP to ISC to Board — ensures that review is transparent and objective, and that ICRF supports research of the highest quality and greatest potential impact.

I first became involved with ICRF in 2007, when I was invited to join a Scientific Review Panel. During my career I've reviewed many papers and grant applications from top U.S. and international investigators, but among the small pile of ICRF applications I was assigned, a few went far beyond anything I had seen in other contexts.

The very best applications to ICRF are characterized by their creativity, their focus on highly significant problems, and the relatively modest budgets they require to accomplish their goals. ICRF support makes an enormous difference to the Israeli scientists that we fund. It's an honor to be part of the process that identifies the top research and brings it forward for funding, and it's a pleasure to work with the many dedicated folks at ICRF who support this effort.

ICRF Peer Review Process

ICRF's peer review process is highly regarded throughout the scientific community for being thorough, transparent, and fair. It is based on the application process used by the National Institutes of Health (NIH).

1 Israeli Scientists Submit Grant Applications



Israeli scientists, based in Israel, submit comprehensive descriptions of their proposed cancer-related research in December.

2 Scientific Review Panels (SRPs) Evaluate Each Proposal



Applications are assigned to one of three scientific review panels. Two reviewers from the assigned panel each provide a detailed evaluation based on:

- Potential to advance diagnosis, treatment, or prevention of cancer
- Innovation, scientific merit, and originality
- Qualifications of the applicant
- Research facilities and intellectual environment
- Budget

3 SRPs Make Recommendations



The SRPs meet annually in March. The U.S. and Canadian experts on the SRPs discuss the applications and assign an overall rating to each one. Funding is based on these ratings.

4 International Scientific Council (ISC) Establishes Funding Priority



ICRF scientific policy is overseen by the ISC, composed of eminent U.S., Canadian, and Israeli cancer researchers. The ISC evaluates the applications based on scores from the SRPs and makes recommendations for funding to the ICRF International Board of Trustees.

5 Board Allocates Resources



ICRF's International Board of Trustees allocates available resources; funding for each grant is continued only if the required progress reports are satisfactory.

75 cancer research projects funded in 2021-2022

Spotlight on the Scientists



"Von Hippel-Lindau (VHL) is an inherited multi-cancer syndrome, characterized by benign and malignant tumors throughout the body. With the generous support of a Clinical Research Career Development Award, our team will focus on studying this cancer using multiple cutting-edge techniques, and hopefully help to promote a cure for VHL-related endocrine cancer and for other cancer types fueled by similar molecular mechanisms. We are thankful for this opportunity to contribute our share in the battle against cancer, together with the ICRF community."

Amit Tirosch, MD

*Chaim Sheba Medical Center
ICRF Clinical Research Career Development Award Recipient*



"Thanks to the ICRF Research Career Development Award, my team and I will study the molecular mechanisms driving pediatric gliomas, tumors originating in the brain and spinal cord, in the hope of gaining deeper understanding and identifying vulnerabilities of these devastating and deadly childhood tumors."

Efrat Shema, PhD

*Weizmann Institute of Science
ICRF Research Career Development Award Recipient*



"I feel fortunate to receive the ICRF Postdoctoral Fellowship Grant. The funding will enable my research into the elusive interactions between immune cells and cancer-associated fibroblasts (a common cell found in connective tissue), which will hopefully lead to a better understanding of cancer biology and lay the foundation for development of immunotherapeutics for solid cancers in breast cancer. The generous funding will also support my development into a future independent researcher."

Aviad Ben-Shmuel, PhD

*Weizmann Institute of Science
ICRF Post Doctoral Fellowship Grant Recipient*



"I am extremely thankful to receive the ICRF Postdoctoral Fellowship grant. This funding is crucial for completion of my research that will reveal whether leukemic cell proliferation can be controlled by modification of the pathways that cause normal cells to change into cancer cells, and hopefully result in novel therapeutic targets to fight cancer."

Adi Rechesh, PhD

*Hebrew University of Jerusalem
ICRF Postdoctoral Fellowship Recipient*



"The ICRF Project Grant will allow my group to develop new computational methods to track the role of a normal cellular aging process (epigenetic degradation) in the initiation and progression of cancer. Our hope is that our work will lead to the identification of new biomarkers that can predict which drugs can effectively target the changes that have occurred in the cancer of a specific patient. The generous funding comes at a critical junction in my research path, as I transition from a U.S.-based lab to an Israeli one. ICRF enables scientists like me in Israel to conduct world-class research."

Benjamin Berman, PhD

*Hebrew University of Jerusalem
ICRF Project Grant Recipient*

Over **2,600** grants funded to date

Spotlight on the Scientists (continued)



"The ICRF Research Career Development Award is wonderful news for our research group. It will enable us to pursue the ambitious goal of developing therapeutics designed to increase the effect of the immune system to control tumors, by shifting the balance of T-cells away from non-responsiveness toward durable long-term protective immunity. On a personal note, the grant came at the perfect time as I take my first steps as an independent researcher in this challenging field."

Asaf Madi, PhD

*Tel Aviv University
ICRF Research Career Development Award Recipient*



"Most immunotherapy protocols do not account for age-related changes in the immune response. Thanks to an ICRF Research Career Development Award, we are now investigating the important and mostly-unaddressed question of how to improve the efficacy of T-cell immunotherapy, which harnesses the power of the immune system to seek out and destroy cancer cells, in the aged."

Noga Ron-Harel, PhD

*Technion, Israel Institute of Technology
ICRF Research Career Development Award Recipient*



"An ICRF Research Career Development Award gives our research team the capability to develop next-generation tools for imaging mechanics in 3D, laying the groundwork for a better understanding of how the immune system interacts within cancerous tissue. It also fosters the development of mentorship networks which are so important for young faculty."

Joshua M. Grolman, PhD

*Technion, Israel Institute of Technology
ICRF Research Career Development Award Recipient*



"I would like to thank you for the very generous ICRF Project Grant. We will be furthering our research on a distinct combination of cannabinoids, which are able to induce cell death in leukemia cells. We are hoping our investigations will optimize treatment for patients with numerous cancers and pave the way for the establishment of a new pharmacotherapy."

David Meiri, PhD

*Technion, Israel Institute of Technology
ICRF Project Grant Recipient*



"I am very grateful for the support of the Len & Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers Grant. Our research aims to develop RNA-specific diagnostic tools that are designed to detect RNA that is associated with ovarian cancer. We believe this will have a huge impact on a patient's quality of life and overall survival."

Eylon Yavin, PhD

*The Hebrew University of Jerusalem
Len & Susan Mark Initiative for
Ovarian and Uterine/MMMT Cancer Grants Recipient*

Stories of Hope

"I have come to appreciate Israel's remarkable contribution to curing cancer. It was Dr. Eli Canaani — with the support of the Israel Cancer Research Fund — whose research led to the development of Gleevec®, a drug that has saved my life! How amazing that I, a Christian man from Jersey, benefited from Israeli research. And I'm hardly alone; people of every faith, around the world, have also benefited."

— **Bill Heywang**

*21-Year Chronic Myelogenous Leukemia Cancer Survivor,
Cancer Research Fundraiser*



"As a cancer survivor, joining ICRF is a gift that words cannot describe. Receiving a cancer diagnosis turned my world upside down. Now to be part of a mission and a team that is helping to bring about changes so one day cancer will not upend so many lives, is humbling."

— **Alan Herman**

*11-Year Adenoid Cystic Carcinoma Survivor,
ICRF New York Executive Director*



"Twelve years later, my neuro-oncologist calls me a unicorn. I know how lucky I am. I don't take it for granted."

— **Bill Meyers**

*12-Year Glioblastoma Survivor,
ICRF Connecticut Board Member,
2021 Ribbons of Hope Honoree*




"In 2005, I was diagnosed with an aggressive form of Chronic Lymphocytic Leukemia. I began a series of treatments, remissions, and relapses, with no remission lasting more than two years. In 2013, I was accepted for a clinical trial. Eight years later, I am one lucky guinea pig! Cancer strikes indiscriminately. Cancer research is an investment in everyone's future, and supporting ICRF is an investment in the future of Israel's scientific community as well."

— **Paul T. Fox**

*16-Year Chronic Lymphocytic Leukemia Survivor,
ICRF Chicago Board Member,
Chairman of Chicago Office,
Greenberg Traurig*


2021 ICRF Ribbons of Hope Virtual Celebration

Over 1,400 attendees tuned into the Israel Cancer Research Fund's second nationwide Ribbons of Hope Virtual Gala for a night of comedy, song, science, and hope. This year's host and honoree, beloved actor and comedian **Richard Kind**, and four chapter honorees, **Cynthia Perl**, **Cindy Pogrud**, **Bill Meyers**, and **Marjorie B. Cohen, z"l**, were celebrated for their tireless dedication and contributions to ICRF's mission by a star-studded lineup of special guests that included **Michael J. Fox**, **Jason Alexander**, **Paul Rudd**, **Hank Azaria**, **Susie Essman**, **Jeff Garlin**, **Gilbert Gottfried**, **Steven Weber**, and **Ayla Schwartz** from the Broadway production of Disney's *Frozen*.



Other noted guests of honor included ICRF-funded scientist, **Jacob Hanna, MD, PhD** of the Weizmann Institute, and inspirational guest speaker, businessman and philanthropist, **Joseph Shamie**, who shared his personal cancer journey. The gala – ICRF's largest fundraising event of the year – raised more than \$1.6 million in support of groundbreaking cancer research at leading institutions across Israel.

To view the video: visit icrfonline.org/gala2021.



"I am so honored to accept this award, and when someday a scientist funded by ICRF makes a huge breakthrough, I will point to that scientist and tell my friends, 'I had a little bit to do with that'."

— **Richard Kind**
2021 ICRF Ribbons of Hope Host and Honoree



"My lab has been supported by ICRF for the last ten years, since day one of its establishment. It's the first grant I ever received, and it has been so crucial because it offers many types of programs that are longer term. Having this stability allows researchers to take on riskier projects, more challenging projects, which I think is critical. Moreover, the ICRF reputation is very positive, and I've often felt that my Research Professorship Grant has facilitated my ability to apply for other grants as well."

— **Jacob Hanna, MD, PhD**
*Weizmann Institute of Science
ICRF Research Professorship Grant Recipient*

"The gala was a unique opportunity to tell the story of Israel's truly world-class research to a national audience."

— **David Abramson**,
President, ICRF International

"We strive to inspire hope for cancer patients and their families worldwide and generate critical dollars in support of Israel's brilliant cancer research. The Virtual Gala exceeded our expectations in so many ways, the most important being that the funds raised will enable us to continue to support the very best cancer research being conducted by ICRF-funded scientists."

— **Beryl P. Chernov**, *ICRF National Executive Director*

2021 Chapter Events Highlights

New York/National*

- Brilliant Minds Monthly Webinar Series*
- Women's Advisory Council "HerMoney: An Intimate Conversation" and Mediterranean Wine Tasting
- Jacki & Bruce Barron Cancer Research Scholars Program Symposium*

Chicago

- Revolving Tables Chicago Visions Young Leadership Networking Event
- Chicago Cancer Symposium
- A Journey of Hope with Jason Rosenthal and Paris Rosenthal

Connecticut

- An Evening of Laughter with Comedian Dan Naturman and Professor Daniel Rosenberg
- Virtual Magic Show: Make Cancer an Illusion

Toronto

- Revolving Tables Toronto Visions Young Leadership Networking Event
- Women of Action Virtual Celebration
- ICRF Presents: Unplugged Musical Entertainment

Montreal

- Women of Action Luncheon


Israel

- "Adopt a Researcher" Major Gifts Campaign

Financials

Annual Research Funding


Millions of Dollars



ICRF Funding Totals Per Institution 1990/1991 – 2020/2021

Institution	Total
Ariel University	\$205,000
Assaf-Harofeh Medical Center	\$150,000
Bar-Ilan University	\$3,950,667
Ben-Gurion University	\$2,205,500
Carmel Hospital	\$319,000
Chaim Sheba Medical Center	\$3,257,500
Hadassah University Hospital	\$2,668,197
Hebrew University	\$16,261,800
Kaplan Hospital	\$85,500
MIGAL - Galilee Technology Center	\$370,000
National Institute of Oceanography	\$105,000
Rabin Medical Center, Beilinson and Golda Campuses	\$528,500
Rambam Medical Center	\$1,531,000
Schneider Children's Medical Center	\$200,000
Shaare Zedek Medical Center	\$882,000
Technion, Israel Institute of Technology	\$8,858,500
Tel-Aviv Sourasky Medical Center	\$530,000
Tel-Aviv University	\$10,060,000
University of Haifa	\$105,000
Volcani Institute	\$30,000
Weizmann Institute of Science	\$11,925,900
Western Galilee Medical Center	\$105,000
Total	\$64,334,064

Sources of Income



Please be advised that amounts reflect no bias and have not been allocated per institution, but impartially to the scientists who scored the highest in ICRF's fully-objective, grant application peer-review process.

A Legacy of Generosity

Planned Giving

With a planned gift to the Israel Cancer Research Fund, you can leave a philanthropic legacy that will help those touched by cancer — now and for years to come. Whether you would like to put your donation to work today or in the future, there are a variety of opportunities for making a legacy commitment. Please visit icrfonline.org/planned-giving to learn how you can create a lasting impact on the future of cancer research.

ICRF Donor Recognition Park in Tel Aviv

ICRF Donor Recognition Park in Tel Aviv, a 4.5 acre oasis of greenery and tranquility, exists as a living monument to the memory of loved ones throughout the world lost to cancer. The park also provides a permanent place of recognition for ICRF's generous benefactors.

The Donor Wall, located at the heart of the park, holds the names of ICRF's generous benefactors that not only share the dream of making cancer history — but also taking proactive steps to make it happen. Visit www.icrfonline.org/icrf-park to explore the park and learn more.

"Over the past three years, my wife and I have lost three dear friends to cancer. We are so impressed with the breakthrough research of ICRF scientists that we've decided to leave a legacy so future generations will not experience such loss. We recently updated our will and I learned that the easiest way was to add ICRF as a beneficiary to my IRA account. All it took was an email to my stockbroker! It feels good knowing that we will be helping humankind even when we are no longer here."

— **Jerry Silber**

*Vice Chairman,
ICRF Connecticut Chapter*



For more information about planned giving or ICRF Park naming opportunities, please contact:

Caitlin Shmidheiser
212-969-9800, ext. 227

caitlin.shmidheiser@icrfonline.org

Your contribution can help save lives!

Make a meaningful impact on cancer research by funding an ICRF grant in your name or in honor of a loved one. A designated grant can be made at every giving level and you will receive information from the researcher.

Named Scientific Grant Opportunities:

Professorship Grants

(\$550,000 over a 5-year period)
Awarded to senior scientists who have made outstanding contributions to cancer research.

Project Grants

(\$198,000 over a 3-year period)
Awarded to established investigators working on a specific cancer research project

Clinical Research Career Development Awards

(\$148,500 over a 3-year period)
Awarded to promising oncologists to conduct clinical research projects early in their career.

Research Career Development Awards

(\$148,500 over a 3-year period)
Awarded to promising investigators to conduct laboratory research projects early in their career.

Postdoctoral Fellowships

(\$99,000 over a 3-year period)
Awarded to new MDs and PhDs to apprentice with senior investigators.

Special Grants:

Acceleration Grants

(\$154,000 over a 2-year period)
Awarded to investigators proposing highly innovative approaches advancing cancer biology and therapeutics.

Collaborative Funding Awards

(\$495,000 over a 3-year period)
Awarded to Israeli scientists working collaboratively with scientists at a North American institution.

Special Funding Initiatives

(Minimum of \$550,000 over a 3-year period) Awarded to investigators conducting cancer research in response to a donor-initiated proposal approved by ICRF's International Scientific Council.

International Board of Trustees 2021

President

David Abramson

Chair

Bryna Goldberg

Vice-Chairman

Rob Densen

First Vice-President

Joel Pelofsky

Vice Presidents

Arnold M. Baskies, MD

Charles Ben Dayan

Jeffrey Bernstein

Treasurer

Richard Edelheit

Secretary

Cynthia Perl

Executive Committee Members

Richard Lipkin

Nancy Maizels, PhD

Charles Serlin

Trustees

Robert Bard

Bruce Barron

Alan Berk

Jeffrey Bly

Benjamin Bonavida, PhD

Louis Brause

Michelle Chrein

Steven B. Cohen

Marsha Deakter

Vera Finkelstein

Bonnie E. Fish

Paul T. Fox

S. Donald Friedman♦

Tamir Gilat

Kenneth E. Goodman

Gary I. Grad, MD

Robert Greene

Maryanne Greenfield

Lesley Heller

Samuel Herzfeld

Yashar Hirshaut, MD

Mark A. Israel, MD

Clive Kabatznik

Ian Kady

Beth Kaplan

Barbara Kasell

Susan Matteson King

Moni Lustig

Michelle Makori

David Malkin, MD

Rhonda Mims

Patrick Mundt

Linnea Olson

Lisa Oved

Tom Peled

Jane Rabhan

Sarah Rosen

Lisa Schoenberg

Sidney J. Winawer, MD♦

Presidents Emeritus

Rob Densen

Harriet Elisofon

Brad Goldhar

Yashar Hirshaut, MD

Harvey Kaylie*

Daniel G. Miller, MD*

Theodore T. Miller, MD

Chairpersons Emeritus

S. Donald Friedman♦

Kenneth E. Goodman

Yashar Hirshaut, MD

Michael Rosenfelt

Leah Susskind*

Eve Wald*

Honorary Board Members

Evelyn Bienenfeld

Benjamin Brafman

Lynda Brafman

Harriet Elisofon

Maralyn Friedman

Faith G. Miller

Steven T. Rosen, MD

Michael Rosenfelt

Judith Sherman

Michel Steinberger

Eve Wald*

National Executive Director

Beryl P. Chernov

* Deceased

♦ Charter Board Member

Chapters

International Executive and New York Regional Offices

52 Vanderbilt Avenue

Suite 1510

New York, NY 10017

212-969-9800

info@icrfonline.org

Chicago

1 Northfield Plaza, Suite 235

Northfield, IL 60093

847-441-1824

chicago@icrfonline.org

Connecticut Area

7 Lumanor Drive

Stamford, CT 06903

203-321-1006

ct@icrfonline.org

Los Angeles

215-760-3388

Montreal

1310 Greene Avenue, Suite 710

Westmount, QC H3Z 2B2

514-481-2723

info@icrfmontreal.org

Toronto

1881 Yonge Street, Box 29, Suite 616

Toronto, ON M4S 3C4

416-487-5246

research@icrf.ca

Israel

26A Habarzel Street

Tel Aviv 6971037

011-972-77-957-7770

contact@icrf.org.il





ICRF's mission is to support the best and brightest scientists conducting groundbreaking cancer research in Israel. Your gift will help bring us closer to our goal of ending the suffering caused by cancer. The answer to cancer is research!

Visit Our Website:

icrfonline.org

Follow Us On Social Media:

@ICRFONLINE

Other Ways To Give:



Facebook Fundraising

Celebrate your birthday or honor a loved one by creating your own fundraiser for ICRF on Facebook. Visit **facebook.com/fund/ICRFONLINE** to get started.



Support ICRF While You Shop With AmazonSmile

Generate donations for ICRF while you shop through AmazonSmile at no cost to you. To participate, simply start shopping at Amazon using **icrfonline.org/amazonsmile** to get to the site or turn AmazonSmile on in the Amazon app (iOS or Android) and select Israel Cancer Research Fund as your nonprofit of choice.



Double The Donation

Double the impact of your donation with a matching gift from your employer. Many employers match employee donations to ICRF and it only takes a few seconds to check if yours is one of them by visiting **doublethedonation.com/icrf**.



Donate Online:

icrfonline.org/support

Donate Via ICRF Mail House:

Israel Cancer Research Fund
P.O. Box 36
Hartsdale, NY 10530

Contact Us:

212-969-9800

info@icrfonline.org

Tax ID (EIN): 51-0181215